1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,301 | 0,317 | 07:54 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ONCODESIGN PRECISION MEDICINE Aktie jetzt für 0€ handeln | |||||
| 17.04. | Oncodesign Precision Medicine Announces Equity Financing of up to 5 Million Euros | 261 | Business Wire | Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic... ► Artikel lesen | |
| 03.04. | Oncodesign Precision Medicine: OPM Announces Its 2024 Annual Results and Clinical Developments | 281 | Business Wire | OPM-101: preclinical work establishing POC in immuno-oncology, end of phase 1 healthy volunteers and preparation for phase 1b/2a Reintegration of OPM-201 into OPM's portfolio of proprietary... ► Artikel lesen | |
| 24.03. | Oncodesign Precision Medicine (OPM) Announces Protocol Submission for its Phase 1b/2a Study, REVERT for OPM-101 in Combination with Pembrolizumab in Patients with Advanced Melanoma Resistant to Anti-PD1 | 347 | Business Wire | OPM-101 will be evaluated in a Phase 1b/2a clinical trial, in combination with pembrolizumab, a monoclonal antibody directed against the PD-1 protein, in patients with advanced melanoma resistant... ► Artikel lesen | |
| 04.03. | Oncodesign Precision Medicine: Nomination of Christophe Thurieau as an Independent Member of OPM Board of Directors | 337 | Business Wire | Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic... ► Artikel lesen | |
| 20.12.24 | Oncodesign Precision Medicine Reacquires Rights to Its OPM-201 Program From Servier After a Positive Phase I Trial in Healthy Volunteers | 385 | Business Wire | Retrieval by OPM of all rights to the OPM-201 program and associated patent portfolio Confirmation of the molecule's safety in healthy volunteers
Regulatory News:
Oncodesign Precision... ► Artikel lesen | |
| 22.10.24 | Oncodesign Precision Medicine: OPM Reports Final Results of Its Phase 1 Study With RIPK2 Inhibitor OPM-101, With Strong Safety Data and No Cardiac Toxicity, Paving the Way for the Launch of Phase 1b/2a | 381 | Business Wire | Finalization of the study report on the double-blind, placebo-controlled Phase 1 trial of OPM-101 in 104 healthy volunteers (HV) who received OPM-101 24-hour ECG analysis reveals no toxic... ► Artikel lesen | |
| 15.10.24 | Oncodesign Precision Medicine: OPM Announces Poster Presentation on OPM-101, a RIPK2 Kinase Inhibitor, in Healthy Volunteers at UEG Week 2024 Conference | 326 | Business Wire | Presentation by Professor Laurent Peyrin-Biroulet (M.D., PhD Professor of Gastroenterology at CHRU of Nancy) and Bruno Robin (PharmD, Head of OPM Clinical Development) of safety, pharmacokinetic... ► Artikel lesen | |
| 25.09.24 | Oncodesign Precision Medicine: OPM Announces Its First-half 2024 Results and Provides an Update on Its Clinical Developments, and Its Financial Situation | 383 | Business Wire | OPM-101 successfully completed its Phase 1 trial with healthy volunteers, enabling the company to anticipate the start of a Phase 1b/2a clinical trial in 2024/early 2025. OPM-201, licensed... ► Artikel lesen | |
| 16.07.24 | Oncodesign Precision Medicine: OPM Announces Positive Results of Its Phase 1 in Healthy Volunteers with OPM-101: Strong Target Engagement With Excellent Safety Profile | 315 | Business Wire | End of double-blind, placebo-controlled phase 1 trial with OPM-101: 104 healthy volunteers (VS) participated in this trial designed to assess the safety of OPM-101 in humans Very good safety... ► Artikel lesen |
9 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SOLID BIOSCIENCES | 4,720 | -1,87 % | Citi startet Berichterstattung für Solid Biosciences mit Kaufempfehlung | ||
| HARMONY BIOSCIENCES | 31,980 | +0,38 % | Mizuho reaffirms Harmony Biosciences stock rating on positive orexin data | ||
| CG ONCOLOGY | 25,950 | -0,46 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
| QIAGEN | 41,000 | -0,56 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
| LYELL IMMUNOPHARMA | 8,940 | -1,97 % | Lyell Immunopharma, Inc. - 8-K, Current Report | ||
| SPRINGWORKS THERAPEUTICS | 46,990 | 0,00 % | SpringWorks Therapeutics, Inc. - 8-K, Current Report | ||
| KYMERA THERAPEUTICS | 44,080 | -3,57 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
| CLIMB BIO | 1,180 | -6,35 % | Climb Bio, Inc.: Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer | Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll... ► Artikel lesen | |
| ADMA BIOLOGICS | 18,160 | -1,30 % | Will Strong Asceniv Sales Drive ADMA Biologics Further? | ||
| ALLOGENE THERAPEUTICS | 1,180 | -1,67 % | Allogene Therapeutics, Inc. - 8-K, Current Report | ||
| RECURSION PHARMACEUTICALS | 5,030 | -6,85 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
| EVOTEC | 7,138 | -0,81 % | Aktienmarkt: Evotec-Aktie kann sich nicht behaupten (6,38 €) | An der deutschen Börse liegt das Wertpapier von Evotec aktuell im Minus. Das Wertpapier notiert zur Stunde bei 6,38 Euro. Am Aktienmarkt liegt die Aktie von Evotec gegenwärtig im Minus. Die Aktie verbilligte... ► Artikel lesen | |
| CARGO THERAPEUTICS | 4,190 | -0,71 % | Pre-market Movers: Leishen Energy, Black Diamond Therapeutics, FST Corp., 5E Advanced Materials, CARGO Therapeutics | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.00 A.M. ET).In the Green Leishen Energy Holding Co., Ltd. (LSE) is up over... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 20,610 | -3,33 % | H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target | ||
| NUVALENT | 79,66 | +0,67 % | Nuvalent, Inc.: Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | Aligned with FDA on NDA submission strategy for TKI pre-treated patients with advanced ROS1-positive NSCLC and participation in Real-Time Oncology Review; the... ► Artikel lesen |
ONCODESIGN PRECISION MEDICINE SA gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,287 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ONCODESIGN PRECISION MEDICINE SA finden Sie auf Wallstreet Online.